The market for chimeric antigen receptor T cell therapies
This article discusses the market for chimeric antigen receptor (CAR) T cell therapies, focusing on haematological malignancies. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 29, 2018 Category: Drugs & Pharmacology Authors: Amy Yip Rachel M. Webster Tags: News and Analysis Source Type: research
Glimmers in illuminating the druggable genome
Nature Reviews Drug Discovery 17, 301 (2018).
doi:10.1038/nrd.2017.252
Authors: Griffin Rodgers, Christopher Austin, James Anderson, Aaron Pawlyk, Christine Colvis, Ronald Margolis & Jenna Baker
Much biomedical research continues to focus on a small proportion of the human genome that has already been studied intensively. The Illuminating the Druggable Genome programme, initiated as a pilot project by the US National Institutes of Health Common Fund in 2014, is now being implemented to accelerate the investigation of subsets of understudied proteins that have potential therapeutic relevance. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 19, 2018 Category: Drugs & Pharmacology Authors: Griffin Rodgers Christopher Austin James Anderson Aaron Pawlyk Christine Colvis Ronald Margolis Jenna Baker Tags: Comment Source Type: research
Impact of a five-dimensional framework on R & D productivity at AstraZeneca
Nature Reviews Drug Discovery 17, 167 (2018).
doi:10.1038/nrd.2017.244
Authors: Paul Morgan, Dean G. Brown, Simon Lennard, Mark J. Anderton, J. Carl Barrett, Ulf Eriksson, Mark Fidock, Bengt Hamrén, Anthony Johnson, Ruth E. March, James Matcham, Jerome Mettetal, David J. Nicholls, Stefan Platz, Steve Rees, Michael A. Snowden & Menelas N. Pangalos
In 2011, AstraZeneca embarked on a major revision of its research and development (R&D) strategy with the aim of improving R&D productivity, which was below industry averages in 2005–2010. A cornerstone of the revised strategy was to focus decision-m...
Source: Nature Reviews Drug Discovery - January 19, 2018 Category: Drugs & Pharmacology Authors: Paul Morgan Dean G. Brown Simon Lennard Mark J. Anderton J. Carl Barrett Ulf Eriksson Mark Fidock Bengt Hamr é n Anthony Johnson Ruth E. March James Matcham Jerome Mettetal David J. Nicholls Stefan Platz Steve Rees Michael A. Snowden Menelas N. Pangalos Tags: Perspectives Source Type: research
Morgan Sheng
Nature Reviews Drug Discovery 17, 88 (2018).
doi:10.1038/nrd.2017.271
In 2006, Genentech re-entered into the neuroscience fray by partnering with AC Immune to develop novel Alzheimer disease treatments. A year and half later, Morgan Sheng joined the biotech firm as Vice President of Neuroscience, and was tasked with putting together a plan to eke new drug candidates out of emerging science. Ten years on, the firm's neuroscience pipeline includes three Alzheimer drugs, one amyotrophic lateral sclerosis drug, one pain drug and a number of preclinical candidates. Sheng spoke with Asher Mullard about his continued fait...
Source: Nature Reviews Drug Discovery - January 19, 2018 Category: Drugs & Pharmacology Tags: News and Analysis Source Type: research
Market watch: 2017 FDA drug approvals: number rebounds but average value slips
Nature Reviews Drug Discovery 17, 87 (2018).
doi:10.1038/nrd.2018.2
Authors: Mathias Baedeker, Michael Ringel, Valery Panier & Ulrik Schulze
In line with our outlook last year (Nat Rev. Drug Discov.16, 78; 2017), there was a rebound in the number of new drugs approved by the FDA in 2017 compared with 2016 (Nat. Rev. Drug Discov. 17, 81–85; (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 19, 2018 Category: Drugs & Pharmacology Authors: Mathias Baedeker Michael Ringel Valery Panier Ulrik Schulze Tags: News and Analysis Source Type: research
2017 FDA drug approvals
Nature Reviews Drug Discovery 17, 81 (2018).
doi:10.1038/nrd.2018.4
Author: Asher Mullard
The FDA approved 46 new drugs last year, the highest total in more than two decades. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 19, 2018 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
mRNA vaccines — a new era in vaccinology
Nature Reviews Drug Discovery 17, 261 (2018).
doi:10.1038/nrd.2017.243
Authors: Norbert Pardi, Michael J. Hogan, Frederick W. Porter & Drew Weissman
mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 12, 2018 Category: Drugs & Pharmacology Authors: Norbert Pardi Michael J. Hogan Frederick W. Porter Drew Weissman Tags: Review Source Type: research
Biased signalling: from simple switches to allosteric microprocessors
Nature Reviews Drug Discovery 17, 243 (2018).
doi:10.1038/nrd.2017.229
Authors: Jeffrey S. Smith, Robert J. Lefkowitz & Sudarshan Rajagopal
G protein-coupled receptors (GPCRs) are the largest class of receptors in the human genome and some of the most common drug targets. It is now well established that GPCRs can signal through multiple transducers, including heterotrimeric G proteins, GPCR kinases and β-arrestins. While these signalling (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - January 5, 2018 Category: Drugs & Pharmacology Authors: Jeffrey S. Smith Robert J. Lefkowitz Sudarshan Rajagopal Tags: Review Source Type: research
Market watch: Upcoming market catalysts in Q1 2018
Nature Reviews Drug Discovery 17, 8 (2018).
doi:10.1038/nrd.2017.263
Author: Tanner Collins
Potential market catalysts in the first quarter of 2018 include important top-line clinical trial results for rigerimod (developed by ImmuPharma and SymBio) for systemic lupus erythematosus (SLE); ofranergene obadenovec (developed by VBL Therapeutics and NanoCarrier) for recurrent glioblastoma (rGBM); and azeliragon (developed by vTv Therapeutics) (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Tanner Collins Tags: News and Analysis Source Type: research
Can innate immune system targets turn up the heat on 'cold' tumours?
Nature Reviews Drug Discovery 17, 3 (2018).
doi:10.1038/nrd.2017.264
Author: Asher Mullard
STING, RIG-I and NLRP3 agonists might increase the effectiveness of immuno-oncology checkpoint inhibitors, while antagonists of these targets offer an anti-inflammatory bonus. (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
Nature Reviews Drug Discovery 17, 78 (2018).
doi:10.1038/nrd.2017.267
Author: Daniella M. Schwartz, Yuka Kanno, Alejandro Villarino, Michael Ward, Massimo Gadina & John J. O'Shea
Nature Reviews Drug Discovery16, 843–862 (2017)In the version of this article that was originally published, there was an error in Figure 3 on page 847. In this figure, the structure attributed to the compound BMS-986165 is (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Daniella M. Schwartz Yuka Kanno Alejandro Villarino Michael Ward Massimo Gadina John J. O'Shea Tags: Corrigendum Source Type: research
Cancer: Inhibiting DNA damage signalling
Nature Reviews Drug Discovery 17, 18 (2018).
doi:10.1038/nrd.2017.261
Author: Sarah Crunkhorn
The DNA transposase, piggyBac transposable element-derived 5 (PGBD5), is expressed in the majority of childhood solid tumours, where it promotes site-specific genomic rearrangements. Henssen et al. hypothesized that PGBD5-expressing cells may depend on active DNA damage repair and signalling for survival. Indeed, cell lines (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Technology: New method for endogenous protein degradation
Nature Reviews Drug Discovery 17, 18 (2018).
doi:10.1038/nrd.2017.260
Author: Sarah Crunkhorn
Current strategies to modulate protein expression rely on DNA knock out or RNA interference. A novel method — Trim-Away — can directly and rapidly degrade endogenous proteins in mammalian cells, minimizing the risk of phenotype compensation and off-target effects. Trim-Away introduces exogenous TRIM21 (an E3 (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Immunotherapy: Vaccine patch to treat melanoma
Nature Reviews Drug Discovery 17, 18 (2018).
doi:10.1038/nrd.2017.259
Author: Sarah Crunkhorn
The use of whole tumour cell preparations in cancer immunotherapy, to simultaneously target multiple tumour antigens to activate the immune response, is a promising therapeutic approach. Ye et al. have developed a transdermal microneedle vaccine patch that directly targets antigen-presenting cells via delivery of (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
Cancer: Targeting telomeres
Nature Reviews Drug Discovery 17, 18 (2018).
doi:10.1038/nrd.2017.258
Author: Sarah Crunkhorn
Telomere maintenance enables the indefinite proliferation potential of cancer cells and is among the most frequent alterations in human glioblastoma (GBM). Here, Bejarano et al. report that expression of the telomere binding protein TRF1 — essential for telomere capping and protection — is upregulated (Source: Nature Reviews Drug Discovery)
Source: Nature Reviews Drug Discovery - December 28, 2017 Category: Drugs & Pharmacology Authors: Sarah Crunkhorn Tags: Research Highlight Source Type: research
